98%
921
2 minutes
20
Study Objective: To compare surgical outcomes of patients with uterine neoplasia undergoing total laparoscopic hysterectomy only (TLH) with those having TLH and lymph node dissection (TLHND) from September 5, 1996 through January 13, 2007.
Design: Retrospective chart analysis (Canadian Task Force classification II-2).
Setting: Three tertiary surgical centers in California.
Patients: 112 patients with uterine neoplasia operated on from 1996 through 2006.
Interventions: All patients underwent total laparoscopic hysterectomy and bilateral salpingoophorectomy; however, 30 patients with FIGO stage IC or higher, lymph channel involvement, or grade 3 disease also underwent pelvic and aortic node dissection.
Measurements And Main Results: Of 807 patients having TLH, 112 had a uterine neoplasia: twenty-one hyperplasia, 86 carcinoma, 2 ovarian and endometrial carcinoma, and 3 low-grade endometrial stromal sarcoma; 82 had TLH and adnexectomy; and 30 had TLHND. For both groups, the mean age was 60 (NS), Quatlet index was 31.2 (NS), parity was 1.6 (NS), and the mean blood loss was 148 mL (NS). The node dissection added 56 minutes to TLH (132 vs 188 minutes, p <.001) and yielded a mean of 25 nodes. Patients in both groups spent a median of 1 day in the hospital (NS). There were 7 complications (6.3%) in the series: among the patients in the TLH group, 1 conversion to laparotomy for bleeding from an ovarian artery, 1 vaginal rupture during coitus at 6 weeks, and 1 nonsurgical episode of diverticulitis. There were 4 patients in the TLHLND group with complications: 1 ureteral injury, 1 trocar-site hernia, 1 vaginal laceration, and 1 pelvic abscess.
Conclusions: Node dissection added 56 minutes and entailed no additional blood loss, transfusion, or length of hospital stay, as well as minimal risk of complication. Total laparoscopic hysterectomy with indicated lymph node dissections for endometrial disease is reasonably well tolerated and warrants prospective randomized study to document its role in the therapy of endometrial carcinoma.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jmig.2007.02.012 | DOI Listing |
Psychooncology
September 2025
Department of Clinical Nursing, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.
Background: Sub-Saharan Africa (SSA) bears the highest global burden of cervical cancer. Living with the disease is a complex experience, leading to significant changes across various biopsychosocial dimensions, which in turn affect the quality of life of affected women.
Aims: This review aimed to synthesize available scientific evidence on the life experiences of women diagnosed with cervical cancer in SSA in order to generate valuable insights into the care of the affected population.
J Int Med Res
September 2025
Department of Hepatobiliary Surgery, The Affiliated People's Hospital of Ningbo University, China.
This study explores effective treatment methods for chronic secondary lymphedema after radical cervical cancer surgery combined with pelvic lymphadenectomy. In cases where conservative treatment was ineffective, we investigated whether multiple injections of indocyanine green can effectively improve the outcomes of lymphatic-venous anastomosis under microscopy. Preoperative lymphatic imaging was used to localize functional vessels, guiding distal left lower limb lymphatic reconstruction.
View Article and Find Full Text PDFAnn Behav Med
January 2025
Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, MD 20850, United States.
Background: Hispanic/Latina women in the United States have high rates of cervical cancer and little is known regarding how sociocultural factors might be related to their cervical cancer prevention behaviors.
Purpose: Two studies examined correlates of human papillomavirus (HPV) vaccine initiation, HPV vaccine completion, ever screening for cervical cancer, and being up to date with screening among screening- and vaccine-eligible Hispanic/Latina women.
Methods: Study 1 examined sociodemographic correlates of these behaviors using data from the Behavioral Risk Factor Surveillance System.
Pol Merkur Lekarski
September 2025
LLC "ECOFARM", KYIV, UKRAINE.
Objective: Aim: To consider the specific activity of drops and suppositories of PROTEFLAZID® at the stage of preclinical study, to assess the effectiveness and safety of use in clinical practice in papillomavirus-associated diseases of the female reproductive system..
Patients And Methods: Materials and Methods: Analysis of scientific publications on the treatment of palilomavirus infection with PROTEFLAZID® in women over the past decade.
Epidemiol Serv Saude
September 2025
Universidade Federal do Rio Grande do Norte, Natal, RN, Brazil.
Objectives: To assess the time taken to diagnose cervical cancer in Brazil and identify associated sociodemographic and clinical factors in the period 2016-2020.
Methods: This was a cross-sectional study of cervical neoplasms diagnosed between 2016 and 2020, using data collected from the Hospital Cancer Registry. The logistic regression model was applied to calculate odds ratios (OR) and 95% confidence intervals (95%CI).